L&R Announces Launch of Debrisoft® Active Monofilament Debriding Device for U.S. Wound Care Market
Topeka, KS – April 13, 2015 – Lohmann & Rauscher (L&R) is pleased to announce the launch of Debrisoft® Active Monofilament Debriding Device for the U.S. wound care market. Debrisoft has been available in Europe for several years where it has rapidly established itself as a proven alternative to both traditional and advanced debriding products.
Designed to overcome the limitations and drawbacks of alternative techniques, Debrisoft employs millions of angled polyester fibers which quickly loosen non-viable material and spares viable granulation and epithelial tissue with virtually no trauma or pain. The open pile construction encourages loosened debris and exudate to freely enter the pile where it is sequestered for removal from the wound bed.
Debrisoft has established itself as a debridement method preferred by both patients and clinicians. Patients appreciate the fact that debridement is accomplished in just a few minutes without the pain associated with alternative techniques. Clinicians note how using Debrisoft allows rapid visualization of the wound bed speeding wound evaluation and treatment planning. Debridement can begin as soon as the wound dressing is removed without the need to wait for anesthesia or analgesia to take effect. The enhanced absorption and sequestration properties ensure debris, biofilm and other barriers to wound healing are removed and not accumulated on the surface of the device to be spread over the wound surface.
Debrisoft may be used to enhance the effectiveness of other debridement techniques to reduce procedure times and ensure the maximum degree of wound bed preparation. For example, adding Debrisoft to surgical or sharps technique extends debridement to the smallest debris fragments and biofilm over the entire wound surface. When used to complement passive enzymatic or autolytic techniques, Debrisoft rapidly removes dissolved necrosis then goes a step further to remove additional debris and biofilm left behind. Ideally suited for maintenance debridement, the wound bed may be frequently cleared of the barriers to healing without the risk or discomfort experienced with alternative active techniques.
The NICE guidance published in March 2014 supports the case for adopting the Debrisoft monofilament debridement device as part of the management of acute and chronic wounds. The benefits that the Debrisoft pad are likely to provide include faster debridement with reduced frequency and number of episodes of care, good tolerance by patients, convenience, ease of use, and cost savings.
Debrisoft will be presented at the L&R exhibit at the SAWC and WHS symposium in San Antonio April 30 to May 2, 2015.
About Lohmann & Rauscher
Lohmann & Rauscher (L&R) is an internationally operating supplier of premium medical devices and hygiene products. Created in 1998 from the merger of two long-established companies, Lohmann (founded in 1851) and Rauscher (founded in 1899), L&R has over 160 years of experience in the development, production and sales of bandages and medical products.
The company’s headquarters are located at the Rengsdorf (Germany) and Vienna (Austria) sites. In 2000, L&R integrated with an established US office and distribution center in Topeka, KS to form Lohmann & Rauscher, Inc. As a global manufacturer and supplier of key components, L&R has more than 130 partners in over 80 countries on all continents
Contact L&R Customer Service, phone: 800-279-3863, fax: 800-289-1903, e-mail: office@us.LRmed.com for additional information on the Debrisoft Monofilament Debridement Device.